• Diabetes

Januvia Generic Name & Formulations

General Description

Sitagliptin (as phosphate) 25mg, 50mg, 100mg; tabs.

Pharmacological Class

Dipeptidyl peptidase-4 (DPP-4) inhibitor.

How Supplied

Tabs 25mg, 50mg—30, 90, 100; 100mg—30, 90, 100, 1000


Generic Availability


Januvia Indications


Adjunct to diet and exercise in type 2 diabetes, as monotherapy or combination therapy.

Limitations of Use

Not for treatment of type 1 diabetes. Not studied in patients with history of pancreatitis.

Januvia Dosage and Administration


100mg once daily. Renal impairment: eGFR ≥30–<45mL/min/1.73m2: 50mg once daily; eGFR <30mL/min/1.73m2 or ESRD on dialysis: 25mg once daily.


<18yrs: not established.

Januvia Contraindications

Not Applicable

Januvia Boxed Warnings

Not Applicable

Januvia Warnings/Precautions


Assess renal function before starting therapy and periodically thereafter. Consider risks/benefits in patients with known risk factors for heart failure; monitor for signs/symptoms; evaluate and consider discontinuing if develops. Monitor for pancreatitis, serious hypersensitivity reactions, severe joint pain, or bullous pemphigoid; discontinue if suspected or occurs. History of angioedema to other DPP-4 inhibitors. Severe hepatic impairment. Elderly. Pregnancy. Nursing mothers.

Januvia Pharmacokinetics

See Literature

Januvia Interactions


May need lower dose of concomitant sulfonylurea or insulin to reduce risk of hypoglycemia.

Januvia Adverse Reactions

Adverse Reactions

Upper respiratory tract infection, nasopharyngitis, headache; pancreatitis, heart failure, hypersensitivity reactions (eg, anaphylaxis, angioedema, Stevens-Johnson syndrome), severe and disabling arthralgia, bullous pemphigoid.

Januvia Clinical Trials

See Literature

Januvia Note

Not Applicable

Januvia Patient Counseling

See Literature